Loading…

Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration

Therapeutic monoclonal antibodies and endogenous IgG antibodies show limited uptake into the central nervous system (CNS) due to the blood-brain barrier (BBB), which regulates and controls the selective and specific transport of both exogenous and endogenous materials to the brain. The use of natura...

Full description

Saved in:
Bibliographic Details
Published in:mAbs 2018-07, Vol.10 (5), p.765-777
Main Authors: Karaoglu Hanzatian, Denise, Schwartz, Annette, Gizatullin, Farid, Erickson, Jamie, Deng, Kangwen, Villanueva, Ruth, Stedman, Christopher, Harris, Cristina, Ghayur, Tariq, Goodearl, Andrew
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c411t-784fd424554fa2d57b3e669acb700e72c880cb9309556c9707361a4343a984a93
cites cdi_FETCH-LOGICAL-c411t-784fd424554fa2d57b3e669acb700e72c880cb9309556c9707361a4343a984a93
container_end_page 777
container_issue 5
container_start_page 765
container_title mAbs
container_volume 10
creator Karaoglu Hanzatian, Denise
Schwartz, Annette
Gizatullin, Farid
Erickson, Jamie
Deng, Kangwen
Villanueva, Ruth
Stedman, Christopher
Harris, Cristina
Ghayur, Tariq
Goodearl, Andrew
description Therapeutic monoclonal antibodies and endogenous IgG antibodies show limited uptake into the central nervous system (CNS) due to the blood-brain barrier (BBB), which regulates and controls the selective and specific transport of both exogenous and endogenous materials to the brain. The use of natural transport mechanisms, such as receptor-mediated transcytosis (RMT), to deliver antibody therapeutics into the brain have been studied in rodents and monkeys. Recent successful examples include monovalent bispecific antibodies and mono- or bivalent fusion proteins; however, these formats do not have the capability to bind to both the CNS target and the BBB transport receptor in a bivalent fashion as a canonical antibody would. Dual-variable-domain immunoglobulin (DVD-Ig) proteins offer a bispecific format where monoclonal antibody-like bivalency to both the BBB receptor and the therapeutic target is preserved, enabling independent engineering of binding affinity, potency, valency, epitope and conformation, essential for successful generation of clinical candidates for CNS applications with desired drug-like properties. Each of these parameters can affect the binding and transcytosis ability mediated by different receptors on the brain endothelium differentially, allowing exploration of diverse properties. Here, we describe generation and characterization of several different DVD-Ig proteins, specific for four different CNS targets, capable of crossing the BBB through transcytosis mediated by the transferrin receptor 1 (TfR1). After systemic administration of each DVD-Ig, we used two independent methods in parallel to observe specific uptake into the brain. An electrochemiluminescent-based sensitive quantitative assay and a semi-quantitative immunohistochemistry technique were used for brain concentration determination and biodistribution/localization in brain, respectively. Significantly enhanced brain uptake and retention was observed for all TfR1 DVD-Ig proteins regardless of the CNS target or the systemic administration route selected.
doi_str_mv 10.1080/19420862.2018.1465159
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6150631</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2041629931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-784fd424554fa2d57b3e669acb700e72c880cb9309556c9707361a4343a984a93</originalsourceid><addsrcrecordid>eNpVkclOHDEQhq0IxIyARyDqYy49lN1e2pdIYQkgjcQFOCFZNW43cdIbthuJt2c6swjq4ipX_b9L_gg5o7CgUMI51ZxBKdmCAS0XlEtBhf5G5tN9DqWCg30u2YycxvgXplBAFRyRGdNKUcn0nDxfBPRdNg4J_7msr7N2bJJ_w8Z1KcOu2tR5HJz1tbfZ1dNVfveSDaFPzncxwzq5kMX3mFy7bmPV-s7HFDD5vjshhzU20Z1uz2Py-Pv64fI2X97f3F3-WuaWU5pyVfK64owLwWtklVCrwkmp0a4UgFPMliXYlS5ACyGtVqAKSZEXvEBdctTFMfm58R3GVesqu949YGOG4FsM76ZHb752Ov_HvPRvRlIBsqBrgx9bg9C_ji4m0_poXdNg5_oxGgZ8-i79f1RsRm3oYwyu3j9DwUxwzA6OmeCYLZy17vvnHfeqHYriA_cbitM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2041629931</pqid></control><display><type>article</type><title>Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration</title><source>PubMed Central(OA)</source><creator>Karaoglu Hanzatian, Denise ; Schwartz, Annette ; Gizatullin, Farid ; Erickson, Jamie ; Deng, Kangwen ; Villanueva, Ruth ; Stedman, Christopher ; Harris, Cristina ; Ghayur, Tariq ; Goodearl, Andrew</creator><creatorcontrib>Karaoglu Hanzatian, Denise ; Schwartz, Annette ; Gizatullin, Farid ; Erickson, Jamie ; Deng, Kangwen ; Villanueva, Ruth ; Stedman, Christopher ; Harris, Cristina ; Ghayur, Tariq ; Goodearl, Andrew</creatorcontrib><description>Therapeutic monoclonal antibodies and endogenous IgG antibodies show limited uptake into the central nervous system (CNS) due to the blood-brain barrier (BBB), which regulates and controls the selective and specific transport of both exogenous and endogenous materials to the brain. The use of natural transport mechanisms, such as receptor-mediated transcytosis (RMT), to deliver antibody therapeutics into the brain have been studied in rodents and monkeys. Recent successful examples include monovalent bispecific antibodies and mono- or bivalent fusion proteins; however, these formats do not have the capability to bind to both the CNS target and the BBB transport receptor in a bivalent fashion as a canonical antibody would. Dual-variable-domain immunoglobulin (DVD-Ig) proteins offer a bispecific format where monoclonal antibody-like bivalency to both the BBB receptor and the therapeutic target is preserved, enabling independent engineering of binding affinity, potency, valency, epitope and conformation, essential for successful generation of clinical candidates for CNS applications with desired drug-like properties. Each of these parameters can affect the binding and transcytosis ability mediated by different receptors on the brain endothelium differentially, allowing exploration of diverse properties. Here, we describe generation and characterization of several different DVD-Ig proteins, specific for four different CNS targets, capable of crossing the BBB through transcytosis mediated by the transferrin receptor 1 (TfR1). After systemic administration of each DVD-Ig, we used two independent methods in parallel to observe specific uptake into the brain. An electrochemiluminescent-based sensitive quantitative assay and a semi-quantitative immunohistochemistry technique were used for brain concentration determination and biodistribution/localization in brain, respectively. Significantly enhanced brain uptake and retention was observed for all TfR1 DVD-Ig proteins regardless of the CNS target or the systemic administration route selected.</description><identifier>ISSN: 1942-0862</identifier><identifier>EISSN: 1942-0870</identifier><identifier>DOI: 10.1080/19420862.2018.1465159</identifier><identifier>PMID: 29771629</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>Animals ; Antibodies, Bispecific - administration &amp; dosage ; Antibodies, Bispecific - pharmacokinetics ; Antibodies, Monoclonal - administration &amp; dosage ; Antibodies, Monoclonal - pharmacokinetics ; Antigens, CD - metabolism ; Biological Transport ; Blood-Brain Barrier - metabolism ; Brain - metabolism ; Electrochemical Techniques ; Humans ; Immunohistochemistry ; Luminescent Measurements ; Mice, Inbred C57BL ; Receptors, Transferrin - metabolism ; Tissue Distribution ; Transcytosis</subject><ispartof>mAbs, 2018-07, Vol.10 (5), p.765-777</ispartof><rights>2018 Taylor &amp; Francis Group, LLC 2018 Taylor &amp; Francis Group, LLC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-784fd424554fa2d57b3e669acb700e72c880cb9309556c9707361a4343a984a93</citedby><cites>FETCH-LOGICAL-c411t-784fd424554fa2d57b3e669acb700e72c880cb9309556c9707361a4343a984a93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150631/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150631/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29771629$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karaoglu Hanzatian, Denise</creatorcontrib><creatorcontrib>Schwartz, Annette</creatorcontrib><creatorcontrib>Gizatullin, Farid</creatorcontrib><creatorcontrib>Erickson, Jamie</creatorcontrib><creatorcontrib>Deng, Kangwen</creatorcontrib><creatorcontrib>Villanueva, Ruth</creatorcontrib><creatorcontrib>Stedman, Christopher</creatorcontrib><creatorcontrib>Harris, Cristina</creatorcontrib><creatorcontrib>Ghayur, Tariq</creatorcontrib><creatorcontrib>Goodearl, Andrew</creatorcontrib><title>Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration</title><title>mAbs</title><addtitle>MAbs</addtitle><description>Therapeutic monoclonal antibodies and endogenous IgG antibodies show limited uptake into the central nervous system (CNS) due to the blood-brain barrier (BBB), which regulates and controls the selective and specific transport of both exogenous and endogenous materials to the brain. The use of natural transport mechanisms, such as receptor-mediated transcytosis (RMT), to deliver antibody therapeutics into the brain have been studied in rodents and monkeys. Recent successful examples include monovalent bispecific antibodies and mono- or bivalent fusion proteins; however, these formats do not have the capability to bind to both the CNS target and the BBB transport receptor in a bivalent fashion as a canonical antibody would. Dual-variable-domain immunoglobulin (DVD-Ig) proteins offer a bispecific format where monoclonal antibody-like bivalency to both the BBB receptor and the therapeutic target is preserved, enabling independent engineering of binding affinity, potency, valency, epitope and conformation, essential for successful generation of clinical candidates for CNS applications with desired drug-like properties. Each of these parameters can affect the binding and transcytosis ability mediated by different receptors on the brain endothelium differentially, allowing exploration of diverse properties. Here, we describe generation and characterization of several different DVD-Ig proteins, specific for four different CNS targets, capable of crossing the BBB through transcytosis mediated by the transferrin receptor 1 (TfR1). After systemic administration of each DVD-Ig, we used two independent methods in parallel to observe specific uptake into the brain. An electrochemiluminescent-based sensitive quantitative assay and a semi-quantitative immunohistochemistry technique were used for brain concentration determination and biodistribution/localization in brain, respectively. Significantly enhanced brain uptake and retention was observed for all TfR1 DVD-Ig proteins regardless of the CNS target or the systemic administration route selected.</description><subject>Animals</subject><subject>Antibodies, Bispecific - administration &amp; dosage</subject><subject>Antibodies, Bispecific - pharmacokinetics</subject><subject>Antibodies, Monoclonal - administration &amp; dosage</subject><subject>Antibodies, Monoclonal - pharmacokinetics</subject><subject>Antigens, CD - metabolism</subject><subject>Biological Transport</subject><subject>Blood-Brain Barrier - metabolism</subject><subject>Brain - metabolism</subject><subject>Electrochemical Techniques</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Luminescent Measurements</subject><subject>Mice, Inbred C57BL</subject><subject>Receptors, Transferrin - metabolism</subject><subject>Tissue Distribution</subject><subject>Transcytosis</subject><issn>1942-0862</issn><issn>1942-0870</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpVkclOHDEQhq0IxIyARyDqYy49lN1e2pdIYQkgjcQFOCFZNW43cdIbthuJt2c6swjq4ipX_b9L_gg5o7CgUMI51ZxBKdmCAS0XlEtBhf5G5tN9DqWCg30u2YycxvgXplBAFRyRGdNKUcn0nDxfBPRdNg4J_7msr7N2bJJ_w8Z1KcOu2tR5HJz1tbfZ1dNVfveSDaFPzncxwzq5kMX3mFy7bmPV-s7HFDD5vjshhzU20Z1uz2Py-Pv64fI2X97f3F3-WuaWU5pyVfK64owLwWtklVCrwkmp0a4UgFPMliXYlS5ACyGtVqAKSZEXvEBdctTFMfm58R3GVesqu949YGOG4FsM76ZHb752Ov_HvPRvRlIBsqBrgx9bg9C_ji4m0_poXdNg5_oxGgZ8-i79f1RsRm3oYwyu3j9DwUxwzA6OmeCYLZy17vvnHfeqHYriA_cbitM</recordid><startdate>20180704</startdate><enddate>20180704</enddate><creator>Karaoglu Hanzatian, Denise</creator><creator>Schwartz, Annette</creator><creator>Gizatullin, Farid</creator><creator>Erickson, Jamie</creator><creator>Deng, Kangwen</creator><creator>Villanueva, Ruth</creator><creator>Stedman, Christopher</creator><creator>Harris, Cristina</creator><creator>Ghayur, Tariq</creator><creator>Goodearl, Andrew</creator><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180704</creationdate><title>Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration</title><author>Karaoglu Hanzatian, Denise ; Schwartz, Annette ; Gizatullin, Farid ; Erickson, Jamie ; Deng, Kangwen ; Villanueva, Ruth ; Stedman, Christopher ; Harris, Cristina ; Ghayur, Tariq ; Goodearl, Andrew</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-784fd424554fa2d57b3e669acb700e72c880cb9309556c9707361a4343a984a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Antibodies, Bispecific - administration &amp; dosage</topic><topic>Antibodies, Bispecific - pharmacokinetics</topic><topic>Antibodies, Monoclonal - administration &amp; dosage</topic><topic>Antibodies, Monoclonal - pharmacokinetics</topic><topic>Antigens, CD - metabolism</topic><topic>Biological Transport</topic><topic>Blood-Brain Barrier - metabolism</topic><topic>Brain - metabolism</topic><topic>Electrochemical Techniques</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Luminescent Measurements</topic><topic>Mice, Inbred C57BL</topic><topic>Receptors, Transferrin - metabolism</topic><topic>Tissue Distribution</topic><topic>Transcytosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karaoglu Hanzatian, Denise</creatorcontrib><creatorcontrib>Schwartz, Annette</creatorcontrib><creatorcontrib>Gizatullin, Farid</creatorcontrib><creatorcontrib>Erickson, Jamie</creatorcontrib><creatorcontrib>Deng, Kangwen</creatorcontrib><creatorcontrib>Villanueva, Ruth</creatorcontrib><creatorcontrib>Stedman, Christopher</creatorcontrib><creatorcontrib>Harris, Cristina</creatorcontrib><creatorcontrib>Ghayur, Tariq</creatorcontrib><creatorcontrib>Goodearl, Andrew</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>mAbs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karaoglu Hanzatian, Denise</au><au>Schwartz, Annette</au><au>Gizatullin, Farid</au><au>Erickson, Jamie</au><au>Deng, Kangwen</au><au>Villanueva, Ruth</au><au>Stedman, Christopher</au><au>Harris, Cristina</au><au>Ghayur, Tariq</au><au>Goodearl, Andrew</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration</atitle><jtitle>mAbs</jtitle><addtitle>MAbs</addtitle><date>2018-07-04</date><risdate>2018</risdate><volume>10</volume><issue>5</issue><spage>765</spage><epage>777</epage><pages>765-777</pages><issn>1942-0862</issn><eissn>1942-0870</eissn><abstract>Therapeutic monoclonal antibodies and endogenous IgG antibodies show limited uptake into the central nervous system (CNS) due to the blood-brain barrier (BBB), which regulates and controls the selective and specific transport of both exogenous and endogenous materials to the brain. The use of natural transport mechanisms, such as receptor-mediated transcytosis (RMT), to deliver antibody therapeutics into the brain have been studied in rodents and monkeys. Recent successful examples include monovalent bispecific antibodies and mono- or bivalent fusion proteins; however, these formats do not have the capability to bind to both the CNS target and the BBB transport receptor in a bivalent fashion as a canonical antibody would. Dual-variable-domain immunoglobulin (DVD-Ig) proteins offer a bispecific format where monoclonal antibody-like bivalency to both the BBB receptor and the therapeutic target is preserved, enabling independent engineering of binding affinity, potency, valency, epitope and conformation, essential for successful generation of clinical candidates for CNS applications with desired drug-like properties. Each of these parameters can affect the binding and transcytosis ability mediated by different receptors on the brain endothelium differentially, allowing exploration of diverse properties. Here, we describe generation and characterization of several different DVD-Ig proteins, specific for four different CNS targets, capable of crossing the BBB through transcytosis mediated by the transferrin receptor 1 (TfR1). After systemic administration of each DVD-Ig, we used two independent methods in parallel to observe specific uptake into the brain. An electrochemiluminescent-based sensitive quantitative assay and a semi-quantitative immunohistochemistry technique were used for brain concentration determination and biodistribution/localization in brain, respectively. Significantly enhanced brain uptake and retention was observed for all TfR1 DVD-Ig proteins regardless of the CNS target or the systemic administration route selected.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>29771629</pmid><doi>10.1080/19420862.2018.1465159</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1942-0862
ispartof mAbs, 2018-07, Vol.10 (5), p.765-777
issn 1942-0862
1942-0870
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6150631
source PubMed Central(OA)
subjects Animals
Antibodies, Bispecific - administration & dosage
Antibodies, Bispecific - pharmacokinetics
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - pharmacokinetics
Antigens, CD - metabolism
Biological Transport
Blood-Brain Barrier - metabolism
Brain - metabolism
Electrochemical Techniques
Humans
Immunohistochemistry
Luminescent Measurements
Mice, Inbred C57BL
Receptors, Transferrin - metabolism
Tissue Distribution
Transcytosis
title Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A34%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Brain%20uptake%20of%20multivalent%20and%20multi-specific%20DVD-Ig%20proteins%20after%20systemic%20administration&rft.jtitle=mAbs&rft.au=Karaoglu%20Hanzatian,%20Denise&rft.date=2018-07-04&rft.volume=10&rft.issue=5&rft.spage=765&rft.epage=777&rft.pages=765-777&rft.issn=1942-0862&rft.eissn=1942-0870&rft_id=info:doi/10.1080/19420862.2018.1465159&rft_dat=%3Cproquest_pubme%3E2041629931%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c411t-784fd424554fa2d57b3e669acb700e72c880cb9309556c9707361a4343a984a93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2041629931&rft_id=info:pmid/29771629&rfr_iscdi=true